L-Tyrosine
|
Basic information |
| Metabolite name | L-Tyrosine |
 | HMDB0000158 |
 |
C00082 |
 |
6057 |
| Synonyms | Tyrosine; |
| No. of studies | 110 |
|
Basic information |
| Metabolite name | L-Tyrosine |
| HMDB0000158 |
|
C00082 |
|
6057 |
| Synonyms | Tyrosine; |
| No. of studies | 110 |
|
Relationship between L-Tyrosine and depression (count: 110) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M003 | Type1 | day 27 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M004 | Type2 | CUMS + xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + middle dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Up |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type2 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Down |
| Study M031 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M034 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M037 | Type2 | placebo treatment group one-week vs. baseline | Serum | Human | Up |
| Study M037 | Type2 | sertraline treatment group four-week vs. baseline | Serum | Human | Up |
| Study M037 | Type2 | placebo treatment group four-week vs. baseline | Serum | Human | Up |
| Study M050 | Type3 | 14h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M051 | Type3 | fluoxetine group vs. control group | Astrocyte | Sprague-Dawley rat | Up |
| Study M062 | Type1 | CUMS group vs. control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M069 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M070 | Type1 | depressed group vs. non-depressed group | Urine | Human | Down |
| Study M072 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M072 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + Anemarrhena saponins and Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M076 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M087 | Type2 | esketamine group 2-h vs. baseline | Plasma | Human | Down |
| Study M090 | Type1 | depressed group vs. control group | Urine | Human | Down |
| Study M090 | Type2 | depressed group 6-week treatment vs. baseline | Urine | Human | Up |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | Wistar rat | Up |
| Study M097 | Type1 | depressed women group vs. control women group | Urine | Human | Down |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Down |
| Study M1023 | Type1 | CRS group vs. control group | Faece | C57BL/6 J mouse | Up |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1039 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M1039 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M1039 | Type2 | CUMS + high dose of Angelicae Sinensis Radix group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M1042 | Type1 | CUMS + MCAO group vs. MCAO group | Faece | Sprague-Dawley rat | Down |
| Study M1054 | Type1 | CUMS group vs. control group | Plasma | ICR mouse | Down |
| Study M1054 | Type2 | CUMS + ChaihuYujinxiang granules group vs. CUMS group | Plasma | ICR mouse | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Up |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M1091 | Type1 | CMS vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1092 | Type1 | CMS group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1092 | Type3 | venlafaxine group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1095 | Type1 | CUMS group vs. control group | Faece | ICR mouse | Down |
| Study M1095 | Type2 | CUMS + matrine group vs. CUMS group | Faece | ICR mouse | Up |
| Study M1097 | Type2 | probiotic-treated depression group vs. placebo-treated depression group | Faece | Human | Down |
| Study M1098 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1098 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M110 | Type1 | SD group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M1102 | Type1 | nitenpyram group vs. control group, female offspring | Faece | ICR mouse | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Up |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M132 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M132 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M136 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M136 | Type2 | CUMS + high dose of ZZHPD group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M137 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M137 | Type2 | CUMS + hypericin group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M137 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M458 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M483 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M512 | Type1 | CUMS group vs. control group | Plasma | Goto-Kakizaki rat | Down |
| Study M523 | Type1 | CUMS group vs. control group | Brain | Wistar rat | Down |
| Study M542 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M542 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M544 | Type1 | PSD group vs. stoke group | Plasma | Human | Down |
| Study M547 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M577 | Type1 | female depression group vs. female control group, aged 20-29 | Urine | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 20-29 | Plasma | Human | Unknown |
| Study M579 | Type1 | postpartum depression group vs. control group | Urine | Human | Down |
| Study M581 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M583 | Type1 | PSD group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + low dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + venlafaxine group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M594 | Type1 | CRS group vs. control group | Entorhinal cortex | C57BL/6 mouse | Up |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M629 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + high dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M636 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M636 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M668 | Type1 | PSD group vs. stroke group | Urine | Human | Up |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Down |
| Study M689 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Down |
| Study M705 | Type1 | maternal separation group vs. control group | Striatum | C57BL/6 mouse | Down |
| Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Serum | C57BL/6J mouse | Down |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Unknown |
| Study M741 | Type2 | MDD group, post vs. before SSRI treatment | Plasma | Human | Up |
| Study M757 | Type1 | PSD group vs. stroke group | Urine | Human | Down |
| Study M760 | Type1 | CUMS group vs. control group | Hippocampus | Rat | Down |
| Study M766 | Type1 | CUS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M768 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M779 | Type2 | depression group, post vs. before treatment | Plasma | Human | Up |
| Study M790 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M790 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M790 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + taxifolin spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M820 | Type3 | multiple-dose nefazodone group vs. multiple-dose control group | Brain | ICR mouse | Down |
| Study M821 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M830 | Type1 | corticosterone group vs. control group | Brain | Swiss mouse | Down |
| Study M830 | Type2 | corticosterone + acupoint catgut embedding group vs. corticosterone group | Brain | Swiss mouse | Up |
| Study M835 | Type1 | CRS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Down |
| Study M847 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M858 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M859 | Type2 | reserpine + solution group vs. reserpine group | Hippocampus | Sprague-Dawley rat | Down |
| Study M859 | Type2 | reserpine + hydrogel group vs. reserpine group | Hippocampus | Sprague-Dawley rat | Down |
| Study M867 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M867 | Type2 | CUMS + Baihe-Dihuang Tang group vs. CUMS group | Urine | Sprague-Dawley rat | Unknown |
| Study M869 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Down |
| Study M873 | Type1 | ovariectomy + CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M873 | Type2 | ovariectomy + CUMS + Xiang-Su volatile oil group vs. ovariectomy + CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M877 | Type1 | depressed COPD group vs. COPD group | Plasma | Human | Down |
| Study M882 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M882 | Type1 | CUMS group vs. control group | Jejunum | Sprague-Dawley rat | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Down |
| Study M911 | Type1 | CUS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M928 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M947 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M947 | Type2 | CUMS + middle dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M947 | Type2 | CUMS + high dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M956 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M969 | Type1 | CUMS group vs. control group | Hippocampus | ICR mouse | Up |
| Study M969 | Type2 | CUMS + Changyu Daotan Decoction group vs. CUMS group | Hippocampus | ICR mouse | Down |
| Study M971 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M971 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M971 | Type2 | CUMS + Tao-Hong-Si-Wu decoction group vs. CUMS group | Serum | Sprague-Dawley rat | Up |